STING-activating drug delivery systems:Design strategies and biomedical applications  

作　　者：Chunying Li Yifan Zhang Yilin Wan Jingle Wang Jing Lin Zhiming Li Peng Huang 

机构地区：[1]Department of Dermatology and Venereology,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou 325000,China [2]Marshall Laboratory of Biomedical Engineering,International Cancer Center,Laboratory of Evolutionary Theranostics(LET),School of Biomedical Engineering,Shenzhen University Health Science Center,Shenzhen 518060,China [3]Department of Medical Oncology,The Third Affiliated Hospital of Shanghai University,Wenzhou 325000,China

出　　处：《Chinese Chemical Letters》2021年第5期1615-1625,共11页中国化学快报（英文版）

基　　金：This work is financially supported by National Key R&D Program of China(No.2018YFA0704000);National Natural Science Foundation of China(No.82071985);Basic Research Program of Shenzhen(Nos.JCYJ20180507182413022,JCYJ20170412111100742);Guangdong Province Natural Science Foundation of Major Basic Research and Cultivation Project(No.2018B030308003);Shenzhen Science and Technology Program(No.KQTD20190929172538530);the Fok Ying-Tong Education Foundation for Young Teachers in the Higher Education Institutions of China(No.161032).

摘　　要：The stimulator of interferon genes(STING)shows promising clinical activity in infectious diseases and tumors.However,the lack of targeting capability and intracellular stability of STING agonists severely limits the therapeutic efficacy.Recently,drug delivery systems(DDSs)overcome these delivery barriers of STING agonists via passive or active cell targeting,prolonged blood circulation and drug release,and lysosome escape,etc.In this review,we will describe in detail how existing DDSs are designed to overcome delivery barriers and activate the STING pathway,and the current biomedical applications of STING-activating DDSs in the treatments of infectious diseases and tumors.Finally,the prospects and challenges of DDSs in STING activation are discussed.

关 键 词：STING agonist Drug delivery system Cancer treatment Anti-virus treatment IMMUNOTHERAPY 

分 类 号：R943[医药卫生—药剂学] TQ460.1[医药卫生—药学]